-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
On September 10, Wuhan Youzhiyou Biopharmaceutical Co.
According to the information on the official website of Youzhiyou Biology, M701 is a recombinant anti-EpCAM and CD3 human-mouse chimeric bispecific antibody product for injection.
M802 is a recombinant anti-HER2 and CD3 humanized bispecific antibody product for injection.
Previously, these two CD3-targeted double antibody projects have been clinically approved in China
With the completion of the B-2 round of financing, Youzhiyou Bio obtained the B-round financing led by Tongde Investment, BGI, Sanhua Hongdao, Wuhan Biotechnology Research Institute and other institutions participated in the completion of the B round of financing, and the financing amount exceeded 250 million yuan
Reference materials:
[1]Youzhiyou Biotech completed the B-2 round of financing.
[2] Yzybio official website.